Neoadjuvant chemotherapy in hormone receptor-positive/HER2-negative early breast cancer: When, why and what?Rosalba Torrisi, Armando Santoro, Emilia Marrazzo et al.|Critical Reviews in Oncology/Hematology|2021Cited by 63
Platinum salts in the treatment of BRCA-associated breast cancer: A true targeted chemotherapy?Rosalba Torrisi, Armando Santoro, Monica Zuradelli et al.|Critical Reviews in Oncology/Hematology|2019Cited by 33
Predictive Factors of Eribulin Activity in Metastatic Breast Cancer PatientsRita De Sanctis, Armando Santoro, Elisa Agostinetto et al.|Oncology|2018Cited by 20
Insights for the application of TILs and AR in the treatment of TNBC in routine clinical practiceAgnese Losurdo, Armando Santoro, Rita De Sanctis et al.|Scientific Reports|2020Cited by 15
Prognostic factors and outcome of HER2+ breast cancer with CNS metastasesGiovanna Masci, Armando Santoro, Elisa Agostinetto et al.|Future Oncology|2020Cited by 12